These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 7612408)

  • 21. Lesson of the month: selective use of cyclophosphamide in pregnancy for severe autoimmune respiratory disease.
    Nelson-Piercy C; Agarwal S; Lams B
    Thorax; 2016 Jul; 71(7):667-8. PubMed ID: 27033023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up.
    Tochimoto A; Kawaguchi Y; Hara M; Tateishi M; Fukasawa C; Takagi K; Nishimagi E; Ota Y; Katsumata Y; Gono T; Tanaka E; Yamanaka H
    Mod Rheumatol; 2011 Jun; 21(3):296-301. PubMed ID: 21240620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunosuppressive therapy in interstitial lung diseases and immunologically-induced pneumonitis].
    Müller-Quernheim J; Dalhoff K; Schnabel A
    Internist (Berl); 1997 Jun; 38(6):553-61. PubMed ID: 9265000
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
    Volkmann ER; Tashkin DP
    Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
    Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
    Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases.
    Takahashi T; Asano Y; Amiya E; Hatano M; Tamaki Z; Ozeki A; Watanabe A; Kawarasaki S; Nakao T; Taniguchi T; Ichimura Y; Toyama T; Watanabe M; Hirata Y; Nagai R; Sato S
    Mod Rheumatol; 2012 Aug; 22(4):598-601. PubMed ID: 22015621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis?
    Pérez Campos D; Estévez Del Toro M; Peña Casanovas A; González Rojas PP; Morales Sánchez L; Gutiérrez Rojas AR
    Reumatol Clin; 2012; 8(2):58-62. PubMed ID: 22317852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.
    Sabnani I; Zucker MJ; Rosenstein ED; Baran DA; Arroyo LH; Tsang P; Zubair M; Rivera V
    Rheumatology (Oxford); 2009 Jan; 48(1):49-52. PubMed ID: 18815156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
    Broad K; Pope JE
    Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scleroderma lung: pathogenesis, evaluation and current therapy.
    van Laar JM; Stolk J; Tyndall A
    Drugs; 2007; 67(7):985-96. PubMed ID: 17488144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?
    Abignano G; Bissell LA; Emery P; Del Galdo F; Buch MH
    Rheumatology (Oxford); 2016 Dec; 55(12):2273-2275. PubMed ID: 27744357
    [No Abstract]   [Full Text] [Related]  

  • 33. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
    Franzolini N; Quartuccio L; De Marchi G; De Vita S
    Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide.
    Numajiri H; Yoshizaki A; Ebata S; Fukasawa T; Yamashita T; Takahashi T; Taniguchi T; Asano Y; Sato S
    J Dermatol; 2018 Jun; 45(6):e140-e141. PubMed ID: 29265579
    [No Abstract]   [Full Text] [Related]  

  • 35. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
    Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new therapy for systemic sclerosis-associated interstitial lung disease.
    Kondoh Y
    Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation and management of alveolitis and interstitial lung disease in scleroderma.
    Latsi PI; Wells AU
    Curr Opin Rheumatol; 2003 Nov; 15(6):748-55. PubMed ID: 14569205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Ro 52 positive dermatomyositis presenting as rapidly progressive interstitial lung disease.
    Conway R; O'Donnell R; Fahy R; Doran MF; Cunnane G; O'Shea FD
    QJM; 2014 Jul; 107(7):593-4. PubMed ID: 24336848
    [No Abstract]   [Full Text] [Related]  

  • 39. [Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):192-5. PubMed ID: 18942346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
    Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
    J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.